Monotherapy Options for Depression and Nicotine Dependence

Primary Recommendation: Bupropion SR

The American College of Cardiology and other guideline societies recommend bupropion SR as the preferred monotherapy option for patients with both depression and nicotine dependence, due to its FDA approval for both conditions and demonstrated efficacy in smokers with depressive symptoms 1, 2
Bupropion SR has dual FDA approval as an antidepressant and a smoking cessation aid, with evidence suggesting it may be particularly beneficial for smoking cessation in persons with depression 3, 1
Bupropion achieves superior abstinence rates compared to placebo, with a relative risk of 1.62 and a trend toward improved efficacy noted in patients with depression history 1

The National Comprehensive Cancer Network recommends starting with 150 mg once daily for 3 days, then increasing to 150 mg twice daily for maintenance, with a treatment duration of at least 8-12 weeks for smoking cessation 2, 1

The National Comprehensive Cancer Network notes that seizure risk is a serious concern with bupropion, with a 0.1% seizure risk, and it should be avoided in patients with epilepsy, brain metastases, or history of seizures 1
Patients requiring opioid therapy should avoid bupropion if combined with naltrexone, and those taking monoamine oxidase inhibitors should avoid bupropion within 14 days 3

Varenicline is the most effective single-agent for smoking cessation but lacks antidepressant properties, making it a second-line choice for this dual-diagnosis population, with superior smoking cessation efficacy compared to bupropion or nicotine patch 1
The standard dosing for varenicline is 0.5 mg once daily for 3 days, then 0.5 mg twice daily for 4 days, then 1 mg twice daily as target dose, with a treatment duration of 12 weeks standard 2

NRT can be considered but is less optimal for this population, with no antidepressant properties and less efficacy than bupropion or varenicline as monotherapy 1, 4
The standard approach for NRT is a 21 mg/24-hour patch for smokers consuming ≥10 cigarettes/day, combined with short-acting NRT for breakthrough cravings, with a treatment duration of at least 12 weeks 4

The guideline society recommends assessing for seizure risk factors, evaluating depression severity, and considering patient-specific factors to select the appropriate monotherapy 1, 3, 2
Combining pharmacotherapy with behavioral counseling is recommended for optimal outcomes, with counseling increasing quit rates from 8.6% to 15.2% compared to brief advice alone 1, 2, 4